COMMUNIQUÉS West-GlobeNewswire
-
Stereotaxis Announces First MAGiC Procedures in the United States
22/04/2026 -
Glyco Harmony Drops Examined - 2026 Consumer-Focused Report on Ingredients, Claims & Label Insights
22/04/2026 -
CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies
22/04/2026 -
Repligen to Report First Quarter 2026 Financial Results
22/04/2026 -
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
22/04/2026 -
Medicines360 and Pharma Dynamics announce the launch of Avibela® in South Africa, Expanding Access to Long‑Acting Contraception and Treatment of Heavy Menstrual Bleeding
22/04/2026 -
Rakovina Therapeutics Presents New Preclinical Data at AACR 2026 Annual Meeting
22/04/2026 -
Elkedonia strengthens Board of Directors with appointment of Pierre d’Epenoux as Independent Chairman
22/04/2026 -
Elkedonia renforce son Comité stratégique avec la nomination de Pierre d'Epenoux comme Président indépendant
22/04/2026 -
Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children
22/04/2026 -
Communiqué de presse : Tzield de Sanofi approuvé aux États-Unis pour retarder l’apparition du diabète de type 1 de stade 3 chez les jeunes enfants
22/04/2026 -
Axomove lève 4 M€ pour accélérer la commercialisation de son dispositif médical numérique de prévention et de rééducation
22/04/2026 -
Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US
22/04/2026 -
Communiqué de presse : Sanofi fait le point sur la soumission réglementaire de Sarclisa en formulation sous-cutanée aux États-Unis
22/04/2026 -
Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration
22/04/2026 -
Ojemda® approuvé dans l’Union européenne comme première thérapie ciblée pour les enfants atteints de gliome pédiatrique de bas grade (pLGG), en rechute ou réfractaire, indépendamment de l’altération de BRAF
22/04/2026 -
Maze Therapeutics Announces $150 Million Registered Offering
22/04/2026 -
pHemmePure Claims Evaluated: Feminine UTI Balance Formula for Vaginal pH Support by Board-Certified Urologist
22/04/2026 -
Curiox Biosystems Signs Master Software License Agreement for Enterprise-Scale Pluto Code Deployment
22/04/2026
Pages